954 patents currently held

123 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

10 more records may belong here and await a decision; they are not counted.

The next term ends in Nov 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

111

Ending by 2030

Nov 2026

Next term end

681

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Immunoglobulin Variable Domains US 11,312,764

Cited by 16 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.

Ends May 2035 · High confidence Also notable

Techniques for Predicting, Detecting and Reducing Aspecific Protein Interference in Assays Involving Immunoglobulin Single Variable Domains US 11,644,471

Cited by 9 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.

Ends Sep 2031 · High confidence Also notable

Medicament Injection Device US D739,932

Cited by 69 later US patents, top 10% of design patents granted in 2015 in our data. Protection runs to 2029.

Ends Sep 2029 · High confidence

Formerly held, still cited

Notable

Novel ANTI-CD38 Antibodies for the Treatment of Cancer US 8,153,765

Cited by 63 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.

now held by Sanofi-Aventis U.S. LLC

Ends Oct 2032 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

4 fees due Nov 23 to 30, 2026 · next Nov 23
12 fees due Dec 6 to 30, 2026 · next Dec 6
13 fees due Jan 2 to 30, 2027 · next Jan 2
14 fees due Feb 1 to 28, 2027 · next Feb 1
17 fees due Mar 1 to 29, 2027 · next Mar 1
16 fees due Apr 1 to 30, 2027 · next Apr 1
25 fees due May 3 to 28, 2027 · next May 3
20 fees due Jun 3 to 30, 2027 · next Jun 3
21 fees due Jul 2 to 30, 2027 · next Jul 2
16 fees due Aug 2 to 27, 2027 · next Aug 2
15 fees due Sep 3 to 29, 2027 · next Sep 3
15 fees due Oct 2 to 30, 2027 · next Oct 2
8 fees due Nov 3 to 10, 2027 · next Nov 3

Which patents, and when each one lapses · Pro

Recent changes

Nov 12Assignment recorded on 1 record: Alt, Stefan and 6 others to Sanofi Recorded Nov 12, 2026, executed Jan 20, 2023. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76728, frame 147.
Nov 4Assignment recorded on 1 record: Sanofi Winthrop Industrie to Sanofi Recorded Nov 4, 2026, executed May 28, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76634, frame 402.
43 of the patents on this record were granted since Aug 16, 2026
4 terms have ended since Aug 16, 2026

What they patent

The 5 largest of its 681 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Biological Materials Related to C-Met	11 in force	to Apr 2032
Improved Immunoglobulin Variable Domains	9 in force	to May 2035
Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents	9 in force	to Dec 2030
Serpin Fusion Polypeptides and Methods of Use Thereof	8 in force	to Apr 2034
Medicament Injection Device	8 in force	to Mar 2033

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 7,741,363	3-Acylindole Derivatives, Preparation and Therapeutic Use Thereof In force Term ends Nov 17, 2026 · High confidence	In force	Term ends Nov 17, 2026	High confidence
US 8,008,310	Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same In force Term ends Dec 20, 2026 · Medium confidence	In force	Term ends Dec 20, 2026	Medium confidence
US 8,003,385	In Vitro Germinal Centers held by Sanofi Pasteur Vaxdesign Corporation In force Term ends Dec 21, 2026 · High confidence	In force	Term ends Dec 21, 2026	High confidence
US 7,641,907	Dengue Serotype 1 Attenuated Strain held by Sanofi Pasteur and Centers for Disease Control and Prevention In force Term ends Jan 1, 2027 · High confidence	In force	Term ends Jan 1, 2027	High confidence
US H002,246	Method for analyzing continuous glucose monitoring data In force Term ends Feb 28, 2027 · Low confidence	In force	Term ends Feb 28, 2027	Low confidence
US 8,609,681	Spirocyclic nitriles as protease inhibitors In force Term ends May 23, 2027 · Medium confidence	In force	Term ends May 23, 2027	Medium confidence
US 7,641,908	Dengue Serotype 2 Attenuated Strain held by Sanofi Pasteur and Centers for Disease Control and Prevention In force Term ends May 31, 2027 · High confidence	In force	Term ends May 31, 2027	High confidence
US 8,608,961	Method for Affinity Chromatography of Antithrombin III held by Sanofi Mature IP In force Term ends Jun 21, 2027 · High confidence	In force	Term ends Jun 21, 2027	High confidence
US 7,709,257	Models for Vaccine Assessment held by Sanofi Pasteur Vaxdesign Corporation In force Term ends Jul 23, 2027 · High confidence	In force	Term ends Jul 23, 2027	High confidence
US 8,992,912	Methods of Use for Antibodies That Specifically Bind to the EPHA2 Receptor In force Term ends Aug 2, 2027 · Medium confidence	In force	Term ends Aug 2, 2027	Medium confidence

10 of 954 patents shown.

Pro members see all 954.

Pro members: see all 954 patents

Also on record, not counted in the 954: 123 patents in force now held by others · 876 patents ended · 651 applications pending · 731 applications abandoned · 1 record of undetermined status. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro